Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index-Reference-Cited by-同舟云学术

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

Published:2013-10-16 Issue:207 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Desnoyers Luc R.¹,Vasiljeva Olga¹,Richardson Jennifer H.¹,Yang Annie¹,Menendez Elizabeth E. M.¹,Liang Tony W.¹,Wong Chihunt¹,Bessette Paul H.¹,Kamath Kathy¹,Moore Stephen J.¹,Sagert Jason G.¹,Hostetter Daniel R.¹,Han Fei¹,Gee Jason¹,Flandez Jeanne¹,Markham Kate¹,Nguyen Margaret¹,Krimm Michael¹,Wong Kenneth R.¹,Liu Shouchun¹,Daugherty Patrick S.²,West James W.¹,Lowman Henry B.¹

Affiliation:

1. CytomX Therapeutics Inc., 343 Oyster Point Boulevard, Suite 100, South San Francisco, CA 94080, USA.

2. Department of Chemical Engineering, University of California, Santa Barbara, Mail Code 5080, Engineering II, Room 3357, Santa Barbara, CA 93106–5080, USA.

Abstract

A proteolytically activatable EGFR Probody demonstrates antitumor efficacy while alleviating toxicity.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference30 articles.

1. Paul Ehrlich's magic bullet concept: 100 years of progress

2. Marketed therapeutic antibodies compendium

3. Antibody-Drug Conjugate Targets

4. Trastuzumab — Mechanism of Action and Use in Clinical Practice

5. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design of environmentally responsive antibodies with pH-sensing synthetic amino acids;Scientific Reports;2024-08-21

2. Integrating molecular dynamics simulation with small‐ and wide‐angle X‐ray scattering to unravel the flexibility, antigen‐blocking, and protease‐restoring functions in a hindrance‐based pro‐antibody;Protein Science;2024-08-15

3. Unlocking the potential of bispecific ADCs for targeted cancer therapy;Frontiers of Medicine;2024-07-23

4. Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC;Journal of Pharmacokinetics and Pharmacodynamics;2024-06-10

5. Homogeneous multi-payload antibody–drug conjugates;Nature Chemistry;2024-05-17